Topical Calcineurin Inhibitors and Lymphoma Risk: Evidence Update with Implications for Daily Practi...
Topical Calcineurin Inhibitors and Lymphoma Risk: Evidence Update with Implications for Daily Practice
About this item
Full title
Author / Creator
Publisher
Cham: Springer International Publishing AG
Journal title
Language
English
Formats
Publication information
Publisher
Cham: Springer International Publishing AG
Subjects
More information
Scope and Contents
Contents
Topical calcineurin inhibitors (TCIs), commercially available since 2000–2001, are the first and only topical medications approved for chronic treatment of atopic dermatitis (AD) in pediatric patients and remain a welcomed alternative to topical corticosteroids. In January 2006, the US Food and Drug Administration (FDA) issued a boxed warning requi...
Alternative Titles
Full title
Topical Calcineurin Inhibitors and Lymphoma Risk: Evidence Update with Implications for Daily Practice
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3669499
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3669499
Other Identifiers
ISSN
1175-0561
E-ISSN
1179-1888
DOI
10.1007/s40257-013-0020-1
